US4801733A
Expired / Lapsed
US
⏱️ 0.0 years remaining
1-substituted tetralin derivatives, their preparation and their use
Assignee: BASF SE
•
Filing: 1985-09-23
•
Granted: 1989-01-31
•
Expires: 2005-09-23
Abstract
Abstract 1-substituted tetralins of the formula I ##STR1## where n, R 1 , R 2 , R 3 , R 4 , R 5 and R 6 have the meanings stated in the description, and their preparation are described. The compounds are useful for the treatment of disorders.
Inventors
- 👤 Hans-Heiner Wuest
- 👤 Fritz-Frieder Frickel
- 👤 Axel Nuerrenbach
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-04 16:21
CPC Classifications
C; C07; C07C; C07C255/00; A; A61; A61P; A61P17/00; A61P29/00; A61P35/00; C07C247/00; C07C247/20; C07C247/24; C07C43/00; C07C43/02; C07C43/20; C07C43/215; C07C43/23; C07C45/00; C07C45/44; C07C45/61; C07C45/67; C07C45/68; C07C45/70; C07C45/71; C07C47/00; C07C47/20; C07C47/235; C07C47/238; C07C47/26; C07C47/27; C07C47/273; C07C47/277; C07C47/52; C07C47/548; C07C47/56; C07C47/57; C07C47/575; C07C49/00; C07C49/20; C07C49/225; C07C49/227; C07C49/237; C07C49/255; C07C49/76; C07C49/794; C07C49/798; C07C49/80; C07C49/813; C07C49/82; C07C49/835; C07C49/84; C07C57/00; C07C57/46; C07C57/50; C07C65/00; C07C65/01; C07C65/19; C07C65/21; C07C65/28; C07C2602/00; C07C2602/02; C07C2602/04; C07C2602/10
Claims Analysis
Total Claims: 12
Claim 1
Independent Claim
104 words
A 1-substituted tetraline of the formula I ##STR9## where n is 0 or 1, R 1 is hydroxyl or C 1 -C 6 -alkoxy, R 2 and R 3 are each hydrogen, halogen, C 1 -C 4 -alkyl or methoxy, R 4 is hydrogen or an acyclic or cyclic alkyl group of not more than 6 carbon atoms, R 5 is hydrogen or C 1 -C 4 -alkyl, and R 6 is --COOR 13 , where R 13 is hydrogen or C 1 -C 8 -alkyl which is unsubstituted or substituted by hydroxyl or C 1 -C 6 -alkoxy and their physiologically tolerated salts.
Claim 2
Dependent Claim
104 words
A 1-substituted tetraline of the formula I ##STR9## where n is 0 or 1, R 1 is hydroxyl or C 1 -C 6 -alkoxy, R 2 and R 3 are each hydrogen, halogen, C 1 -C 4 -alkyl or methoxy, R 4 is hydrogen or an acyclic or cyclic alkyl group of not more than 6 carbon atoms, R 5 is hydrogen or C 1 -C 4 -alkyl, and R 6 is --COOR 13 , where R 13 is hydrogen or C 1 -C 8 -alkyl which is unsubstituted or substituted by hydroxyl or C 1 -C 6 -alkoxy and their physiologically tolerated salts.
Claim 3
Dependent Claim
9 words
The compound of claim 1 which is (E)-4-[2-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-1-propoxy-naphth-2-yl)-1-ethenyl]-benzoic acid.
Claim 4
Dependent Claim
9 words
The compound of claim 1 which is (E)-4-[2-(1-butyloxy-5,6,7,8-tetrahydro-3,5,5,8,8-pentamethylnaphth-2-yl)-1-ethenyl]-benzoic acid.
Claim 5
Dependent Claim
9 words
The compound of claim 1 which is (E)-4-[2-(1-ethoxy-5,6,7,8-tetrahydro-3,5,5,8,8-pentamethylnaphth-2-yl)-1-ethenyl]-benzoic acid.
Claim 6
Dependent Claim
9 words
The compound of claim 1 which is (E)-4-[2-(5,6,7,8-tetrahydro-1,3-dimethoxy-5,5,8,8-tetramethylnaphth-2-yl)-1-ethenyl]-benzoic acid.
Claim 7
Dependent Claim
27 words
A therapeutic composition for treating dermatological disorders comprising a pharmaceutically acceptable carrier and an effective amount of a compound according to claim 1 as the active compound.
Claim 8
Dependent Claim
24 words
The method of treating dermatological disorders in a patient suffering therefrom which comprises administering an effective amount of a compound according to claim 1.
Claim 9
Dependent Claim
28 words
The method of treating dermatological disorders as set forth in claim 7, wherein an effective amount of a compound according to claim 2 is administered to the patient.
Claim 10
Dependent Claim
28 words
The method of treating dermatological disorders as set forth in claim 7, wherein an effective amount of a compound according to claim 3 is administered to the patient.
Claim 11
Dependent Claim
28 words
The method of treating dermatological disorders as set forth in claim 7, wherein an effective amount of a compound according to claim 4 is administered to the patient.
Claim 12
Dependent Claim
28 words
The method of treating dermatological disorders as set forth in claim 7, wherein an effective amount of a compound according to claim 5 is administered to the patient.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1992-01-31 | 1992-08-01 | 1993-01-31 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1996-01-31 | 1996-08-01 | 1997-01-31 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2000-01-31 | 2000-08-01 | 2001-01-31 | $7700.00 | Window Closed / Lapsed |